Live Feeds
● LIVE Updated 1h ago · 14 sources tracked

Ozempic Rival Delivers 25% Weight Loss at Highest Dose in Phase 3 Trial

An experimental weekly injection called retatrutide achieved an average weight reduction of 25 percent among participants taking the highest dose during an 80-week Phase 3 clinical trial. Developed by Eli Lilly, the drug also demonstrated positive effects on related medical issues, including reduced knee pain and improvements in sleep apnea symptoms. Beyond retatrutide, Eli Lilly advanced other pipeline combinations such as EloraTZP, an experimental combination of eloralintide and tirzepatide that delivered greater weight loss and A1C reductions compared to tirzepatide 15 milligrams in adults with obesity and type 2 diabetes.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (14)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Participants taking the highest dose of retatrutide lost an average of 25% of their starting weight over an 80-week period in a Phase 3 trial.
  • ✓ The retatrutide trial reported improvements in knee pain and reductions in sleep apnea symptoms.
  • ✓ Lilly's EloraTZP combination of eloralintide and tirzepatide delivered greater weight loss and A1C reduction versus tirzepatide 15 mg in adults with obesity and type 2 diabetes.
🛡️ Source Corroboration: 14 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Eli Lilly reported Phase 3 clinical trial data for retatrutide showing participants lost an average of a quarter of their starting weight at the highest dose.

Live updates

  1. Retatrutide Phase 3 Trial Shows 25% Weight Loss

    An experimental weekly injection called retatrutide achieved an average weight reduction of 25 percent among participants taking the highest dose during an 80-week Phase 3 clinical trial. Developed by Eli Lilly, the drug also demonstrated positive effects on related medical issues, including reduced knee pain and improvements in sleep apnea symptoms. Beyond retatrutide, Eli Lilly advanced other pipeline combinations such as EloraTZP, an experimental combination of eloralintide and tirzepatide that delivered greater weight loss and A1C reductions compared to tirzepatide 15 milligrams in adults with obesity and type 2 diabetes.

    Why it matters

    The pharmaceutical industry is aggressively pursuing new treatments leveraging amylin and multi-receptor mechanisms following the massive commercial adoption of standard GLP-1 medications like Ozempic and Zepbound. These next-generation combinations seek to push efficacy boundaries further by targeting multiple metabolic pathways simultaneously. The trial results mark a significant benchmark in anti-obesity drug development as developers try to address both severe weight reduction and secondary complications such as joint strain and breathing disorders.

    What is confirmed

    • Participants taking the highest dose of retatrutide lost an average of 25% of their starting weight over an 80-week period in a Phase 3 trial.
    • The retatrutide trial reported improvements in knee pain and reductions in sleep apnea symptoms.
    • Lilly's EloraTZP combination of eloralintide and tirzepatide delivered greater weight loss and A1C reduction versus tirzepatide 15 mg in adults with obesity and type 2 diabetes.

    What to watch next

    • Further regulatory filings and trial data releases for retatrutide and EloraTZP from Eli Lilly.
    • Broader industry updates on amylin-based obesity drug pipelines from competitors like Novo Nordisk.
    Sources used for this update (14)
    1. The Guardian — ‘Godzilla’ of weight-loss drugs could provide other important health benefits
    2. Scientific American — Blockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs
    3. Eli Lilly — Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
    4. Reuters — Experimental Lilly combination drug tops Zepbound in weight-loss trial
    5. USA Today — Lilly's retatrutide GLP-1 delivers average weight loss of 50 pounds
    6. Fierce Biotech — Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
    7. WSJ — Lilly’s Next-Gen Obesity Drug Helps People Lose Even More Weight in Study
    8. CNBC — Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
    9. ScienceAlert — Ozempic Rival Delivers 25% Weight Loss at Highest Dose in Phase 3 Trial
    10. www.sciencealert.com — Ozempic Rival Delivers 25% Weight Loss at Highest Dose in Phase 3 Trial
    11. www.glp3.wiki — Retatrutide Results and Review: The Weight Loss Data by Dose
    12. www.dazzr.com — Ozempic Rival Delivers 25% Weight Loss at Highest Dose in ...
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community